Clinical researches and developments of neoadjuvant therapy in pancreatic cancer
10.3760/cma.j.cn113884-20200519-00278
- VernacularTitle:胰腺癌新辅助治疗临床研究进展
- Author:
Xueli BAI
1
;
Xiang LI
;
Tingbo LIANG
Author Information
1. 浙江大学医学院附属第一医院肝胆胰外科 浙江省重症胰腺疾病诊治技术研究中心 浙江省肝胆胰疾病临床医学研究中心 浙江省胰腺病研究重点实验室，杭州 310000
- From:
Chinese Journal of Hepatobiliary Surgery
2020;26(9):645-650
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer is a kind of fatal diseases with extremely poor prognosis and radical resection is the only way to treat the disease. However, the majority of patients is in advanced stage and loses the chance of surgery when diagnosed. With the application of neoadjuvant therapy, the outcome of pancreatic cancer patients is improved significantly because some patients with advanced disease regain the opportunity of surgery after treatment. Recently, the researches involving in novel regimens, the combination of chemotherapy and radiotherapy, the timing of surgery are hot issues. Accumulative promising results of immunotherapy and targeted therapy are reported in some malignancies, it offers new hope for pancreatic cancer patients. More high-level evidences are strongly required to improve the treatment of pancreatic cancer. Therefore, we reviewed on clinical researches and developments in neoadjuvant therapy for pancreatic cancer.
